
|Articles|June 21, 2004
Drug provides relief to those with overactive bladder
The FDA recently approved trospium (Sanctura, Indevus Pharmaceuticals/Odyssey Pharmaceuticals) for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency. The product launch of trospium is expected to take place during the third quarter of 2004.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
FDA-Approved Sunscreen Filter Bemotrizinol Debuts in New US Products
2
FDA Approves XFG-Targeted COVID-19 Vaccines From Multiple Companies
3
FDA Approves Stelara for Pediatric Ulcerative Colitis
4
COVID-19 in 2026: Why the Virus Still Threatens Vulnerable Patients
5




























